지혈제 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2032년)

The global demand for Hemostatic Agents Market is presumed to reach the market size of nearly USD 5.99 Billion by 2032 from USD 3.11 Billion in 2023 with a CAGR of 7.56% under the study period 2024 - 2032.

Hemostatic agents are substances used to control bleeding by promoting clot formation and stopping hemorrhage. These agents may include topical hemostatic agents applied directly to wounds and systemic medications administered intravenously to manage bleeding disorders or surgical bleeding. They are crucial in various medical procedures, trauma care, and surgery to prevent excessive blood loss and promote tissue healing.

MARKET DYNAMICS

The increasing incidence of surgical procedures, trauma cases, and cardiovascular surgeries worldwide has fueled the demand for hemostatic agents that effectively control bleeding and mitigate the risk of complications during and after surgery. Hemostatic agents play a crucial role in achieving hemostasis, preventing excessive blood loss, and improving patient outcomes, driving their adoption across diverse medical specialties, including general surgery, orthopedics, neurosurgery, and trauma care. Additionally, advancements in hemostatic technologies, such as developing biocompatible and biodegradable hemostatic agents derived from natural or synthetic materials, have enhanced their safety profile and efficacy, propelling market penetration and acceptance among healthcare professionals and patients. Furthermore, the expanding geriatric population and the escalating burden of chronic diseases, such as cardiovascular disorders and cancer, have increased market growth.

Furthermore, the expanding applications of hemostatic agents beyond traditional surgical settings, including emergency medical services, military healthcare, and sports medicine, have broadened their market potential, driving innovation and product development in the hemostatic agents market. Favorable regulatory frameworks, increasing healthcare expenditure, and growing investments in medical research and development are expected to sustain market growth and thrive in market innovation, addressing unmet clinical needs and enhancing patient care in the global healthcare landscape. However, increasing regulatory scrutiny and safety concerns regarding using certain ingredients in hemostatic agents and the emergence of alternative hemostatic technologies likely hamper market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of hemostatic agents. The growth and trends of hemostatic agents industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the hemostatic agents market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product Type

• Active Agents
• Passive Agents
• Combination

By Specialty / Therapeutic Area

• Cardiology
• Cath Lab
• Trauma
• General Surgery
• Obgyn
• Transplant
• Oncology
• Neurology
• Orthopedic
• Plastic Surgery
• Dental
• Others (Urological Surgeries, Pulmonary Surgeries)

By Distribution Channel

• Large Hospital (500+ Beds)
• Medium Hospital (250-499 Beds)
• Small Hospitals (Less Than 250 Beds)

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Hemostatic Agents market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Hemostatic Agents market include Baxter, Ethicon, Inc., BD, B. Braun SE, Pfizer, Inc., Teleflex Incorporated, CryoLife, Inc., Integra LifeSciences, Advanced Medical Solutions Group plc, Gelita AG. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

• 1.1. Report Description
  • 1.1.1. Objective
  • 1.1.2. Target Audience
  • 1.1.3. Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1. Market Research Process
  • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3 . HEMOSTATIC AGENTS - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Product Type
  • 3.7.2 Market Attractiveness Analysis By Specialty / Therapeutic Area
  • 3.7.3 Market Attractiveness Analysis By Distribution Channel
  • 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1. List of Raw Materials
  • 4.2.2. Raw Material Manufactures List
  • 4.2.3. Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1. Direct Marketing
  • 4.4.2. Indirect Marketing
  • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL HEMOSTATIC AGENTS MARKET ANALYSIS BY PRODUCT TYPE

• 5.1 Overview by Product Type
• 5.2 Historical and Forecast Data
• 5.3 Analysis by Product Type
• 5.4 Active Agents Historic and Forecast Sales by Regions
• 5.5 Passive Agents Historic and Forecast Sales by Regions
• 5.6 Combination Historic and Forecast Sales by Regions

6 . GLOBAL HEMOSTATIC AGENTS MARKET ANALYSIS BY SPECIALTY / THERAPEUTIC AREA

• 6.1 Overview by Specialty / Therapeutic Area
• 6.2 Historical and Forecast Data
• 6.3 Analysis by Specialty / Therapeutic Area
• 6.4 Cardiology Historic and Forecast Sales by Regions
• 6.5 Cath Lab Historic and Forecast Sales by Regions
• 6.6 Trauma Historic and Forecast Sales by Regions
• 6.7 General Surgery Historic and Forecast Sales by Regions
• 6.8 ObGyn Historic and Forecast Sales by Regions
• 6.9 Transplant Historic and Forecast Sales by Regions
• 6.10. Oncology Historic and Forecast Sales by Regions
• 6.11 Neurology Historic and Forecast Sales by Regions
• 6.12 Orthopedic Historic and Forecast Sales by Regions
• 6.13 Plastic Surgery Historic and Forecast Sales by Regions
• 6.14 Dental Historic and Forecast Sales by Regions

7 . GLOBAL HEMOSTATIC AGENTS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

• 7.1 Overview by Distribution Channel
• 7.2 Historical and Forecast Data
• 7.3 Analysis by Distribution Channel
• 7.4 Large Hospital (500+ Beds) Historic and Forecast Sales by Regions
• 7.5 Medium Hospital (250-499 Beds) Historic and Forecast Sales by Regions
• 7.6 Small Hospitals (Less than 250 Beds) Historic and Forecast Sales by Regions

8 . GLOBAL HEMOSTATIC AGENTS MARKET ANALYSIS BY GEOGRAPHY

• 8.1. Regional Outlook
• 8.2. Introduction
• 8.3. North America Sales Analysis
  • 8.3.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.3.2. North America By Segment Sales Analysis
  • 8.3.3. North America By Country Sales Analysis
  • 8.3.4. United State Sales Analysis
  • 8.3.5. Canada Sales Analysis
  • 8.3.6. Mexico Sales Analysis
• 8.4. Europe Sales Analysis
  • 8.4.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.4.2. Europe by Segment Sales Analysis
  • 8.4.3. Europe by Country Sales Analysis
  • 8.4.4. United Kingdom Sales Analysis
  • 8.4.5. France Sales Analysis
  • 8.4.6. Germany Sales Analysis
  • 8.4.7. Italy Sales Analysis
  • 8.4.8. Russia Sales Analysis
  • 8.4.9. Rest Of Europe Sales Analysis
• 8.5. Asia Pacific Sales Analysis
  • 8.5.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.5.2. Asia Pacific by Segment Sales Analysis
  • 8.5.3. Asia Pacific by Country Sales Analysis
  • 8.5.4. China Sales Analysis
  • 8.5.5. India Sales Analysis
  • 8.5.6. Japan Sales Analysis
  • 8.5.7. South Korea Sales Analysis
  • 8.5.8. Australia Sales Analysis
  • 8.5.9. South East Asia Sales Analysis
  • 8.5.10. Rest Of Asia Pacific Sales Analysis
• 8.6. Latin America Sales Analysis
  • 8.6.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.6.2. Latin America by Segment Sales Analysis
  • 8.6.3. Latin America by Country Sales Analysis
  • 8.6.4. Brazil Sales Analysis
  • 8.6.5. Argentina Sales Analysis
  • 8.6.6. Peru Sales Analysis
  • 8.6.7. Chile Sales Analysis
  • 8.6.8. Rest of Latin America Sales Analysis
• 8.7. Middle East & Africa Sales Analysis
  • 8.7.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.7.2. Middle East & Africa by Segment Sales Analysis
  • 8.7.3. Middle East & Africa by Country Sales Analysis
  • 8.7.4. Saudi Arabia Sales Analysis
  • 8.7.5. UAE Sales Analysis
  • 8.7.6. Israel Sales Analysis
  • 8.7.7. South Africa Sales Analysis
  • 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE HEMOSTATIC AGENTS COMPANIES

• 9.1. Hemostatic Agents Market Competition
• 9.2. Partnership/Collaboration/Agreement
• 9.3. Merger And Acquisitions
• 9.4. New Product Launch
• 9.5. Other Developments

10 . COMPANY PROFILES OF HEMOSTATIC AGENTS INDUSTRY

• 10.1. Company Share Analysis
• 10.2. Market Concentration Rate
• 10.3. Baxter
  • 10.3.1. Company Overview
  • 10.3.2. Company Revenue
  • 10.3.3. Products
  • 10.3.4. Recent Developments
• 10.4. Ethicon Inc.
  • 10.4.1. Company Overview
  • 10.4.2. Company Revenue
  • 10.4.3. Products
  • 10.4.4. Recent Developments
• 10.5. BD
  • 10.5.1. Company Overview
  • 10.5.2. Company Revenue
  • 10.5.3. Products
  • 10.5.4. Recent Developments
• 10.6. B. Braun SE
  • 10.6.1. Company Overview
  • 10.6.2. Company Revenue
  • 10.6.3. Products
  • 10.6.4. Recent Developments
• 10.7. Pfizer Inc.
  • 10.7.1. Company Overview
  • 10.7.2. Company Revenue
  • 10.7.3. Products
  • 10.7.4. Recent Developments
• 10.8. Teleflex Incorporated
  • 10.8.1. Company Overview
  • 10.8.2. Company Revenue
  • 10.8.3. Products
  • 10.8.4. Recent Developments
• 10.9. CryoLife Inc.
  • 10.9.1. Company Overview
  • 10.9.2. Company Revenue
  • 10.9.3. Products
  • 10.9.4. Recent Developments
• 10.10. Integra LifeSciences
  • 10.10.1. Company Overview
  • 10.10.2. Company Revenue
  • 10.10.3. Products
  • 10.10.4. Recent Developments
• 10.11. Advanced Medical Solutions Group plc
  • 10.11.1. Company Overview
  • 10.11.2. Company Revenue
  • 10.11.3. Products
  • 10.11.4. Recent Developments
• 10.12. Gelita AG
  • 10.12.1. Company Overview
  • 10.12.2. Company Revenue
  • 10.12.3. Products
  • 10.12.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies